Wegovy (Semaglutide 2.4 mg) Nausea Severity Grading Rubric

How often does nausea occur on Wegovy 2.4 mg?

The Wegovy label pools three randomized, double-blind, placebo-controlled trials in adults with obesity or overweight: 2,116 people took 2.4 mg once weekly for up to 68 weeks and 1,261 took placebo. Nausea was reported by 44% versus 16%, vomiting by 24% versus 6%, diarrhea by 30% versus 16%, constipation by 24% versus 11%, and abdominal pain by 20% versus 10%. Any gastrointestinal reaction was reported by 73% versus 47% [1].

Stopping treatment permanently because of an adverse reaction happened in 6.8% versus 3.2%. Nausea accounted for 1.8% versus 0.2%, vomiting 1.2% versus 0%, and diarrhea 0.7% versus 0.1% [1]. STEP 1, the 1,961-person trial behind the weight-loss indication, reported discontinuation for gastrointestinal events in 4.5% versus 0.8% [2]. STEP 2, in 1,210 adults with type 2 diabetes, reported gastrointestinal adverse events in 63.5% versus 34.3% on placebo [3].

The label cautions that adverse reaction rates from one trial cannot be directly compared with those from another, because trial conditions vary widely [1].

What does the label call severe?

The label reports nausea as one pooled category, without splitting it into mild, moderate and severe. Severity appears instead as a separate warning about severe gastrointestinal adverse reactions, reported in 4.1% of people on Wegovy versus 0.9% on placebo [1]. That warning also states that Wegovy is not recommended in patients with severe gastroparesis, and postmarketing reports listed in the label include ileus, intestinal obstruction and severe constipation including fecal impaction [1].

A plain-language description built on intake and hydration

The levels below describe how much food and fluid is going down. They are not official Wegovy severity grades, and the label sets no cut-off points for them.

Level 1: nausea with intake intact. Queasiness comes and goes; meals and drinks go down roughly as usual. The label's escalation schedule runs 0.25 mg weekly for weeks 1 to 4, then 0.5 mg, 1 mg and 1.7 mg in four-week steps, with maintenance from week 17 at 2.4 mg (recommended) or 1.7 mg, and its stated aim is to reduce the risk of gastrointestinal adverse reactions. If a dose is not tolerated during escalation, the label says to consider delaying escalation for 4 weeks [1].

Level 2: intake reduced, fluids still going down. Meals get smaller or are skipped while drinks still stay down. The label warns that Wegovy can cause acute kidney injury due to volume depletion and says to monitor renal function in patients reporting adverse reactions that could lead to volume depletion [1]. In the trials, acute kidney injury occurred at 0.4 versus 0.2 cases per 100 patient-years (7 versus 4 adults), more often in people with prior renal impairment and during dose titration, often after gastrointestinal fluid loss [1].

Level 3: vomiting that prevents fluids from staying down. Fluid loss from vomiting or diarrhea can lead to the volume depletion and acute kidney injury described above [1]. Persistent severe abdominal pain, sometimes radiating to the back, is a separate warning sign: the label describes it as possibly accompanied by vomiting and says Wegovy should promptly be discontinued if pancreatitis is suspected [1].

What the 7.2 mg dose trials showed about nausea

In the two 72-week trials of the 7.2 mg dose, which enrolled 1,311 people on 7.2 mg, 304 on 2.4 mg and 303 on placebo, nausea was reported by 39%, 35% and 13%, vomiting by 22%, 16% and 6%, and discontinuation for gastrointestinal reasons by 3%, 3% and 0.3% [1].